BSE filing, BSE: 541299. Summary written from the filing by ALFA Finder's alert engine.
Dr. Lalchandani Labs Ltd: key numbers
- Share price
- ₹7.07
- Market cap
- ₹6.13 Cr
- Revenue (annual)
- ₹4.19 Cr
- Net profit (annual)
- ₹0.06 Cr
- P/E (TTM)
- 96.3×Sector 52.0×
- Promoter holding
- 32.90%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Lalchandani Labs Ltd
All →Dr. Lalchandani Labs H2 FY26 Results: Net Loss of ₹0.1 Cr
Dr. Lalchandani Labs Ltd reported revenue from operations of ₹2.1 Cr (-8.7% YoY) and a net loss of ₹0.1 Cr for H2 FY26.
- Key figure
- Net loss ₹0.1 Cr
Dr. Lalchandani Labs Board Meeting Date
Dr Lalchandani Labs Limited postponed its May 30 board meeting to June 03, 2026. The delay allows for internal review of financial data before results approval.
Dr. Lalchandani Labs Capacity Expansion: ₹1 Cr Investment
Dr Lalchandani Labs opened a new strategic centre in Dwarka, Delhi. The facility targets a ₹1 Crore annual revenue contribution from local government employee residents.
- Value
- ₹1.00 Cr
Dr. Lalchandani Labs Board Meeting Date
Dr Lalchandani Labs scheduled a board meeting on May 30, 2026, to approve annual audited financial results. The trading window remains closed until June 1.
Dr. Lalchandani Labs Other Announcement
Dr Lalchandani Labs Ltd confirmed it does not meet the 'Large Corporate' criteria for FY 2025-26 under SEBI debt-raising norms. The company reported zero incremental borrowings and no mandatory debt-sourcing requirements as its long-term borrowings remain below the Rs. 1000 crore threshold.
Dr. Lalchandani Labs Debt & Borrowing
Dr Lalchandani Labs Ltd confirmed it does not qualify as a Large Corporate entity for the financial year 2026. The company reported zero outstanding borrowings as of March 31, 2026, and is therefore not subject to SEBI's mandatory debt-raising framework for large entities.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.